31 Aug 21
31 Aug 21

Biocomposites to present data on STIMULAN® and genex® at American Academy of Orthopaedic Surgeons Annual Meeting

STIMULAN is a unique calcium matrix approved: • as an antibiotic carrier for use in bone and soft tissue in EU • to be mixed with antibiotics to treat bacterial infection in soft tissue surrounding bone in Canada • to be used at an infected site in USA

Keele, UK, 31 August 2021 – Biocomposites, an international medical devices company that engineers, manufactures and markets world leading products for use in infection management in bone and soft tissue, is pleased to announce that research results comparing the efficacy of Biocomposites calcium matrix products STIMULAN® and genex® for antimicrobial potency and killing efficacy of bacterial biofilms, will be presented by Paul Stoodley at the American Academy of Orthopaedic Surgeons Annual Meeting (AAOS), being held in San Diego, 31 August – 3 September 2021.

Paul Stoodley, PhD. Director, Campus Microscopy and Imaging Facility (CMIF), Professor, Departments of Microbial Infection and Immunity and Orthopedics, Infectious Diseases Institute, The Ohio State University said: “I am excited to present this research, which shows the effectiveness of both calcium matrix products. STIMULAN® and genex® present similar levels and durations of in vitro antimicrobial activity against pathogens common to orthopaedic infection, and significantly reduce bioburden in both planktonic and biofilm phenotypes. The global increase in infections caused by antibiotic resistant bacteria has required more targeted antibiotic treatment and the flexibility for surgeons managing infection to use their chosen antibiotics at patient-specific concentration levels.”

Michael Harris, Chief Executive Officer of Biocomposites, added: “Against the backdrop of the pandemic, Biocomposites has continued to execute on its strategy of developing and delivering high quality, cost effective, essential products to healthcare systems and patients worldwide. We are delighted to present our research findings at this prestigious event, and to continue to demonstrate that our products can significantly improve patient outcomes.”

Since the last AAOS Annual Meeting, Biocomposites received European approval for mixing STIMULAN with antibiotics: vancomycin, gentamicin and tobramycin, for use in infected bone and soft tissue, and Canadian approval for use in treating bacterial infection in soft tissue surrounding bone, making it the first and only approved calcium matrix that can carry an antibiotic to treat bacterial infection. Biocomposites also launched STIMULAN® Rapid Cure 3cc product in the US, designed specifically for smaller voids in foot and ankle, orthopaedic reconstruction and trauma procedures.

Oral Abstract Session/Presentation title: Comparisons for the efficacy of synthetic bone void fillers for antimicrobial potency and the prevention and killing efficacy of bacterial biofilms: An In-Vitro Study
Abstract: P0990
Presenting Authors: Sean Aiken, Jack R. Brooks, Craig P Delury, PhD, Devandra Dusane, PhD, Nan Jiang, MD, Phillip A Laycock, Paul Stoodley, PhD
Date & Time: 2 September, 07:00 AM – 05:00 PM
Biocomposites booth: #3635

Professor Paul Stoodley is also one of the faculty at the AAOS Instructional Course Lecture (ICL) on “Infection in Arthroplasty: The Basic Science of Bacterial Biofilms in its Pathogenesis, Diagnosis, Treatment, and Prevention” to be held in San Diego on Friday, 3 September, 8:00 AM to 10:00 AM.

Contact for Media enquiries

Optimum Strategic Communications
Mary Clark, Stephen Adams, Katie Flint
Tel: +44 (0)20 3882 9621

About Biocomposites

Biocomposites is an international medical device company that engineers, manufactures and markets world leading products for use in infection management in bone and soft tissue. Based in Keele, UK, it has global operations across Europe, South America, USA, Canada, China and India. Biocomposites is a world leader in the development of innovative calcium compounds and specialty polymer products for surgical use. Its products regenerate bone and target infection risks across a variety of specialties, including musculoskeletal infection, orthopaedics, trauma, spine, foot and ankle, podiatry and sports injuries. Biocomposites products are now used in over 1 million procedures every year and sold in more than 100 countries around the world. Please visit to learn more.

Other news

Listed below is a list of the 4 most recent news updates made by Biocomposties

Visit our News & Events page


Interested in other types of our content? See a list of some of our most recent below.

Explore Library